Acorda Therapeutics Inc. (ACOR)

3.39
0.16 4.51
NASDAQ : Health Technology
Prev Close 3.55
Open 3.56
Day Low/High 3.38 / 3.63
52 Wk Low/High 2.27 / 21.63
Volume 886.72K
Avg Volume 1.52M
Exchange NASDAQ
Shares Outstanding 48.08M
Market Cap 162.99M
EPS 0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biogen Idec's Critical Nerve Repair Drug is Poised for Big News -- Soon

Biogen Idec's Critical Nerve Repair Drug is Poised for Big News -- Soon

Study results from the most important drug in Biogen Idec's pipeline are expected as early as Monday. Here are essential points you need to know.

Acorda To Present At The 33rd Annual J.P. Morgan Healthcare Conference

Acorda To Present At The 33rd Annual J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.

Acorda Announces Initiation Of Phase 3 Clinical Trial For Dalfampridine In Post-Stroke Walking Deficits

Acorda Announces Initiation Of Phase 3 Clinical Trial For Dalfampridine In Post-Stroke Walking Deficits

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in a Phase 3 clinical trial of dalfampridine for the treatment of post-stroke walking deficits (PSWD).

Acorda Announces Initiation Of Phase 3 Trial Of CVT-301 In Parkinson's Disease

Acorda Announces Initiation Of Phase 3 Trial Of CVT-301 In Parkinson's Disease

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in a Phase 3 study of CVT-301 for the treatment of OFF episodes in Parkinson's disease (PD).

Acorda Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference

Acorda Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Michael Rogers, Chief Financial Officer, and Andrew Blight, Chief Scientific Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference in...

Acorda Therapeutics To Present At The Jefferies 2014 Global Healthcare Conference

Acorda Therapeutics To Present At The Jefferies 2014 Global Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Andrew Blight, Chief Scientific Officer, will present at the Jefferies 2014 Global Healthcare Conference in London on Wednesday, November 19 at 9:20am GMT.

Acorda Therapeutics To Present At The Stifel 2014 Healthcare Conference

Acorda Therapeutics To Present At The Stifel 2014 Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.

Acorda Therapeutics To Present At The Credit Suisse 2014 Healthcare Conference

Acorda Therapeutics To Present At The Credit Suisse 2014 Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Michael Rogers, Chief Financial Officer will present at the Credit Suisse 2014 Healthcare Conference in Phoenix on Tuesday, November 11 at 3:30pm MT.

CORRECTING and REPLACING Acorda Therapeutics Reports Third Quarter 2014 Financial Results

CORRECTING and REPLACING Acorda Therapeutics Reports Third Quarter 2014 Financial Results

Eighth paragraph should read:  FAMPYRA® (prolonged-release fampridine tablets) - For the quarter ended September 30, 2014, the Company reported FAMPYRA royalties from sales outside of the U.

First Week of December 20th Options Trading For Acorda Therapeutics (ACOR)

First Week of December 20th Options Trading For Acorda Therapeutics (ACOR)

Investors in Acorda Therapeutics Inc saw new options begin trading this week, for the December 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new December 20th contracts and identified one put and one call contract of particular interest.

Acorda Therapeutics To Host Conference Call To Discuss Third Quarter 2014 Financial Results On October 30, 2014

Acorda Therapeutics To Host Conference Call To Discuss Third Quarter 2014 Financial Results On October 30, 2014

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that it will host a conference call and webcast to report its third quarter 2014 financial results on Thursday, October 30 at 8:30 a.

Acorda Therapeutics Completes Acquisition Of Civitas Therapeutics

Acorda Therapeutics Completes Acquisition Of Civitas Therapeutics

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced it has completed its acquisition of Civitas Therapeutics and obtained global rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of...

Insider Trading Alert - IBKR, C And ACOR Traded By Insiders

Insider Trading Alert - IBKR, C And ACOR Traded By Insiders

Stocks with insider trader activity include IBKR, C and ACOR

Insider Trading Alert - HCN, ACOR And DRII Traded By Insiders

Insider Trading Alert - HCN, ACOR And DRII Traded By Insiders

Stocks with insider trader activity include HCN, ACOR and DRII

Jim Cramer's Top Stock Picks: CMG UA TAP ACOR

Jim Cramer's Top Stock Picks: CMG UA TAP ACOR

Cramer said it's time to start picking up shares of fast-growing restaurant stocks such as Chipotle Mexican Grill while Molson Coors is poised for growth.

Jim Cramer's 'Mad Money' Recap: Are You Ready to Profit From Friday's Panic?

Jim Cramer's 'Mad Money' Recap: Are You Ready to Profit From Friday's Panic?

The monthly unemployment number always hits the market hard but Cramer says there are bargains to be had.

Perilous Reversal Watch: Acorda Therapeutics (ACOR)

Perilous Reversal Watch: Acorda Therapeutics (ACOR)

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "perilous reversal" (up big yesterday but down big today) candidate

How to Trade the Market's Most-Active Stocks: KBH, BBBY, ACOR

How to Trade the Market's Most-Active Stocks: KBH, BBBY, ACOR

Here's how to trade some of the most active stocks on the market right now.

Jim Cramer's 'Mad Money' Recap: Why You Can't Get Too Negative in This Market

Jim Cramer's 'Mad Money' Recap: Why You Can't Get Too Negative in This Market

Investors always need to be prepared for when common sense returns to the market, Cramer says.

Acorda Acquires Civitas Therapeutics for $525M for Parkinson's Treatment

Acorda Acquires Civitas Therapeutics for $525M for Parkinson's Treatment

Acorda Therapeutics is acquiring Civitas Therapeutics in a $525 million cash deal that would provide the buyer access to a late-stage Parkinson's disease treatment.

Why Acorda Therapeutics (ACOR) Stock Is Rising Today

Why Acorda Therapeutics (ACOR) Stock Is Rising Today

Acorda Therapeutics (ACOR) shares are up double digits after announcing that it was buying Civitas Therapeutics for $525 million.

Acorda Therapeutics (ACOR) Moving On Heavy Pre-Market Trading

Acorda Therapeutics (ACOR) Moving On Heavy Pre-Market Trading

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a pre-market mover with heavy volume candidate

Acorda Therapeutics To Acquire Civitas Therapeutics

Acorda Therapeutics To Acquire Civitas Therapeutics

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash.

Acorda Therapeutics And HealthCore To Present Real World Health Economics And Outcomes Data On Multiple Sclerosis Therapy AMPYRA

Acorda Therapeutics And HealthCore To Present Real World Health Economics And Outcomes Data On Multiple Sclerosis Therapy AMPYRA

Results from a large-scale retrospective claims database study assessing real-world use of AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg will be presented by Acorda Therapeutics, Inc.

Acorda Therapeutics To Present At The Aegis Capital 2014 Healthcare And Technology Conference

Acorda Therapeutics To Present At The Aegis Capital 2014 Healthcare And Technology Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Michael Rogers, Acorda’s Chief Financial Officer, will present at the Aegis Capital 2014 Healthcare and Technology Conference.

Acorda Therapeutics To Present At The Morgan Stanley Global Healthcare Conference

Acorda Therapeutics To Present At The Morgan Stanley Global Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.

Acorda Therapeutics To Present At The Baird 2014 Healthcare Conference

Acorda Therapeutics To Present At The Baird 2014 Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, Chief Executive Officer, and Andrew A.

First Week of ACOR April 2015 Options Trading

First Week of ACOR April 2015 Options Trading

Investors in Acorda Therapeutics Inc saw new options begin trading this week, for the April 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Acorda Therapeutics Reports Second Quarter 2014 Financial Results

Acorda Therapeutics Reports Second Quarter 2014 Financial Results

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the second quarter ended June 30, 2014.

Acorda Therapeutics To Host Conference Call To Discuss Second Quarter 2014 Financial Results On July 31, 2014

Acorda Therapeutics To Host Conference Call To Discuss Second Quarter 2014 Financial Results On July 31, 2014

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that it will host a conference call and webcast to report its second quarter 2014 financial results on Thursday, July 31 at 8:30 a.

TheStreet Quant Rating: D (Sell)